MedTrace Logo

Tocilizumab for Painful Chronic Pancreatitis

NCT06426160 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-06-25

No results posted yet for this study

Summary

This placebo-controlled study will investigate the effect of tocilizumab (an anti-interleukin-6 receptor antibody) on symptom burden, physical functioning, and quality of life in patients with chronic pancreatitis.

Conditions

  • Pancreatitis, Chronic

Interventions

DRUG

Tocilizumab 20 MG/ML [Actemra]

Tocilizumab 8 mg/kg every four weeks for 24 weeks.

DRUG

Sodium Chloride 0.9% Inj

Placebo (Sodium chloride) every four weeks for 24 weeks.

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • University of Aarhus

    collaborator OTHER

  • Viborg Regional Hospital

    collaborator OTHER

  • Stanford University

    collaborator OTHER

  • Haukeland University Hospital

    collaborator OTHER

  • Soren Schou Olesen

    lead OTHER

Principal Investigators

  • Søren S Olesen, MD, Ph.D. · Mech-Sense, Department of Gastroenterology, Aalborg University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-21
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06426160 on ClinicalTrials.gov